ASH News Daily - Saturday, December 10, 2011 - (Page B-41)

Now Enrolling Investigating Everolimus* in Diffuse Large B-cell Lymphoma PILLAR-2 PIvotaL Lymphoma triAls of RAD001 Study Description Phase III, double-blind study in poor-risk patients with diffuse large B-cell lymphoma (DLBCL) following complete response to rituximab-containing chemotherapy Study Design† Everolimus for 1 year Randomize 1:1 Screen Placebo for 1 year † Treatment until relapse, unacceptable toxicity, death, or discontinuation for any other reason. Primary Endpoint Disease-free survival For more information • Call 1-800-340-6843 (United States only) • Visit www.thewideprogram.com • Contact your local Novartis Medical Science Liaison *This is an investigational study; there is no guarantee that everolimus will become commercially available for this indication. PILLAR-2 PIvotaL Lymphoma triAls of RAD001 PR WIDE GRAM Worldwide Initiative to Develop Everolimus THE TM mTOR Novartis Pharma AG CH-4002 Basel, Switzerland ©Novartis 2011 February 2011 RAD-1011242 GCT9124 Novartis Pharmaceuticals Corporation East Hanover, NJ 07936 RDGF16847_PILL2_ASH_DN_DR2.indd 1 10/14/11 10:54 AM

Table of Contents for the Digital Edition of ASH News Daily - Saturday, December 10, 2011

ASH News Daily - Saturday, December 10, 2011

https://www.nxtbookmedia.com